Galectin Therapeutics Inc — Cash Flow (NASDAQ:GALT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 20.6 M24.31 M31.06 M32.97 M41.8 M 30.6 M Cash from investing activities 00000 — Cash from financing activities 263 K36.81 M10 M40.03 M31.23 M 15.09 M Free cash flow 20.6 M24.31 M31.06 M32.97 M41.8 M 30.6 M

News

Galectin Therapeutics director Marc Rubin resigns from board

Galectin Therapeutics CFO sells $233k in shares

Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains

oracle, micron tech among market cap stock movers on friday

Galectin Therapeutics stock plummets after FDA feedback on drug

FDA provides feedback on Galectin’s belapectin development program

Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data (NASDAQ:GALT)

Galectin Therapeutics Stock: NAVIGATE Data Validates The Fibrosis Thesis (NASDAQ:GALT)

Belapectin shows promising antifibrotic effects in MASH patients

10x fund sells Galectin Therapeutics (GALT) shares for $246,800

Tesla, Google lead market cap stock movers on Monday

Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know